ELITE PHARMACEUTICALS, INC /NV/ — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 32 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $32M | ↑+119.9% | $19M | ↑+270.7% | 28.5% |
| 2025-09-30 | $36M | ↑+92.4% | $14M | ↑+224.2% | 22.6% |
| 2025-06-30 | $40M | ↑+113.9% | $-6M | ↓-1055.7% | 54.0% |
| 2025-03-31 | $32M | ↑+78.3% | $7M | ↑+97.8% | 34.9% |
| 2024-12-31 | $14M | ↓-7.6% | $-11M | ↓-1642.0% | 7.6% |
| 2024-09-30 | $19M | ↑+33.4% | $-11M | ↓-173.9% | 18.5% |
| 2024-06-30 | $19M | ↑+109.4% | $616K | ↓-46.1% | 20.6% |
| 2024-03-31 | $18M | ↑+107.7% | $3M | — | 20.8% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$32M
↑+119.9% +$17M YoY
Net Income
$7M
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 63 quarters
margin trajectory tells the operating-leverage storyGross Margin↓-1.6pts
41.0%
Operating Margin↑+20.9pts
28.5%
Net Margin↑+134.7pts
58.9%
Go deeper
ELTP Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyELTP Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics